Abstract Sentinel node biopsy (SNB) for axillary staging in breast cancer allows the application of more extensive pathologic examination techniques. Micrometastases are being detected more often, however, coinciding with stage migration. Besides assessing the prognostic relevance of micrometastases and the need for administering adjuvant systemic and regional therapies, there still seems to be room for improvement. In a population-based analysis, we compared survival of patients with sentinel node micrometastases with those with node-negative and node-positive disease in the era after introduction of SNB. Data from the population-based Eindhoven Cancer Registry were used on all (n = 6803) women who underwent SNB for invasive breast cancer in the Southeast Region of The Netherlands in the period 1996-2006. In 451 patients (6.6%) a sentinel node micrometastasis (pN1mi) was detected and in 126 patients (1.9%) isolated tumor cells (pN0(i?)). Micrometastases or isolated tumor cells in the SNB did not convey any significant survival difference compared with nodenegative disease. After adjustment for age, pT, and grade, still no survival difference emerged pN1mi: [HR 0.9 (95% CI, 0.6-1.3)] and pN0(i?): [HR 0.4 (95% CI, 0.14-1.3)] and neither was the case after additional adjustment for adjuvant systemic therapy. Our practice-based study showed that the presence of sentinel node micrometastases in breast cancer patients has hardly any impact on breast cancer overall survival during the first years after diagnosis.
Introduction
During the past decades, an increase in breast cancer incidence has occurred [1] . Combined with improving survival rates this implies that the number of prevalent breast cancer cases will continue to rise as well as the health care burden of breast cancer. Sentinel node biopsy (SNB) as an axillary staging procedure in primary breast cancer was introduced about 10 years ago to avoid axillary lymph node dissection (ALND) in patients with tumor-negative lymph nodes. The main advantage of performing SNB is a markedly lower morbidity [2, 3] whereas axillary staging capacities are similar to ALND [4, 5] . A randomized trial showed the 8-year survival of patients with primary breast cancer to be equal in the SNB-group and the ALND-group [6] . Furthermore, in observational research with cancer registry data, survival of patients with negative SNB without completion ALND has been shown to be at least equivalent to the survival of nodenegative patients with extensive ALND [7] . These findings support the validity and safety of SNB as a staging procedure, and thus, the removal of clinically negative axillary lymph nodes by ALND seems no longer justifiable.
Since only a few nodes are being removed, the introduction of the SNB led to the application of more extensive time-consuming and costly pathologic examination techniques like serial sectioning and immunohistochemistry. Occult metastases or micrometastases were detected in 9-23% of originally Hematoxylin & Eosin node-negative cases [8] . Recent studies showed a 4.3-10% increase among patients diagnosed with micrometastatic disease in the sentinel node as well [9, 10] . This increase led to stage migration after adjustment for the simultaneous, favorable trend in tumor size [9] . A discussion followed on prognostic significance and possible need for additional systemic and regional treatment. Some studies on the prognostic significance of micrometastases in ALND before introduction of the SNB showed that patients with axillary micrometastases had higher recurrence rates and lower overall survival [11] [12] [13] [14] , others, however, demonstrated no such difference [15, 16] . Although most studies with larger sample sizes and longer follow-up tend to show a negative effect of micrometastatic disease on overall and disease-free survival [17, 18] , comparison between these retrospective studies and extrapolation to patients with SNB is hampered by different inclusion criteria and large technical variances in the assessment of micrometastases.
The purpose of our study was to perform a populationbased analysis to determine survival of patients with sentinel node micrometastases as compared to patients with sentinel node-negative and sentinel node-positive disease and, thus, comment on the prognostic value of these micrometastases in the era after introduction of SNB.
Patients and methods
Methodology, results, and discussion of this study were reported according to the REMARK criteria on reporting of tumor marker studies [19] . Patient data were retrieved from the population-based Eindhoven Cancer Registry, which records data on all patients newly diagnosed with cancer in the Southeast region of The Netherlands, an area with approximately 2.4 million inhabitants. Collected data were derived from 10 hospitals, consisting of large non-university teaching hospitals and community hospitals, and two radiotherapy departments. Data on patient and tumor characteristics and local and systemic treatment were collected by the Cancer Registry based on the pathology reports and medical records. The patients were staged according to the Tumor-Node-Metastasis (TNM) system of the International Union Against Cancer (UICC) [20] .
Sentinel node biopsy followed by ALND was introduced in the Southeast Netherlands in 1995. In 1997, surgeons gradually started to perform SNB procedures as a routine staging procedure, and since 2000, indications for SNB were described in national guidelines [21] . We included all women who underwent SNB for primary invasive breast cancer in the Southeast Netherlands in the period 1996-2006, and we used characteristics and data of the entire group in the analyses.
In The Netherlands, the pathology protocol advocated by the EORTC Breast Cancer Group has been adopted by the pathologists since 2000 and included in the Dutch evidencebased guideline for the treatment of breast cancer. According to this guideline, sentinel nodes should be investigated at three levels at 0.25 mm intervals and from each section at least two slides should be made: one for H&E staining and one for IHC [21] . For this study, data were categorized according to axillary lymph node status. Node-negative patients were categorized as pN0. Patients with metastases smaller than 0.2 mm were categorized as pN0(i?) (isolated tumor cells) and as pN1mi (micrometastases) in the case of metastases between 0.2 and 2.0 mm. Node-positive patients were categorized as pN1a if 1 to 3 axillary lymph nodes were positive and [pN1a if more than 3 axillary lymph nodes were positive or if metastases were present in supraclavicular or internal mammary lymph nodes. The discrimination between micrometastases and isolated tumor cells in the Cancer Registration data has only been made since 2003, after introduction of the revised TNM system in 2002.
Follow-up was completed until January 2008, and endpoint of the study was the question whether the patient was still alive. This information was obtained from the municipal registries in the area of the Eindhoven Cancer Registry and the Central Bureau for Genealogy. The latter institution collects data on all deceased Dutch citizens via the municipal registries. In this way, information on patients who moved outside the registry area was also obtained. The few patients (\0.3%) who died outside The Netherlands might be wrongly considered as ''being alive.'' Statistical analyses were carried out using SAS (version 9.1 for Windows, SAS institute Inc, Cary, NC). Survival analyses were carried out using the Kaplan-Meier life table analysis. Survival time was defined as the period between the diagnosis of breast cancer and death or date of last available follow-up. Patients were stratified according to sentinel lymph node status and survival comparison between these groups was performed by means of the log-rank test. We censored the data if the effective sample size was smaller than 10 in the overall survival analyses. Multivariate analyses were carried out using Cox proportional hazards analyses. Variables that showed a significant influence on survival in univariate analyses were entered in the multivariate model. We adjusted for the possible confounding influences of age at diagnosis, tumor size (defined as Tstage), and grade. We additionally adjusted for the effects of administrating adjuvant systemic therapy. P-values \0.05 were considered statistically significant.
Results
Between 1996 and 2006, a total of 6803 patients underwent SNB for primary invasive breast cancer in the Southeast region of The Netherlands. Their characteristics stratified according to lymph node status are demonstrated in Table 1 . Micrometastatic lymph node involvement was observed in 6.6% of the patients. Age at diagnosis, pT-stage, grade, and histology all differed significantly according to nodal status (P \ 0.0001). Patients without metastases or with micrometastatic disease underwent breast-conserving surgery significantly more frequent than those with macrometastases (P \ 0.0001). Administration of adjuvant systemic therapy significantly increased with lymph node involvement. 28% of the patients with a negative sentinel node received adjuvant systemic therapy (chemo-and/or hormonal therapy) versus 74% in the pN1mi-group and 93% in the pN1a-group. Median follow-up was 50 months for patients with pN0-and pN1mi-disease, 53 months for patients with pN1a-disease, 47 months for patients with [pN1a-disease, and 36 months for patients with pN0(i?)-disease. Overall (unadjusted) survival was significantly worse for patients with pN1a-and [pN1a-disease compared to pN0-disease (P \ 0.0001). Survival of patients with pN0(i?) and pN1mi did not differ significantly from pN0-disease (P = 0.19 and P = 0.52) (Fig. 1) . In multivariate analysis adjusted for age, pT, and grade, no significant survival difference was shown between isolated tumor cells and node-negative disease [HR 0.4 (95% CI, 0.14-1.3)] or between micrometastatic disease and node-negative disease [HR 0.9 (95% CI, 0.6-1.3)] ( Table 2) . Patients with pN1a-disease had an increased risk of overall mortality with a hazard ratio of 1.4 (95% CI, 1.2-1.7) compared to pN0. Patients with [pN1a-disease had a hazard ratio of 2.2 (95% CI, 1.7-3.0) compared to pN0.
After additional adjustment for adjuvant systemic therapy still no significant survival difference was observed for isolated tumor cells (P = 0.15) and micrometastatic disease (P = 0.97) compared to node-negative patients. Patients with pN1a-disease and [pN1a-disease still had an increased risk of overall mortality (Table 2 ). We performed additional analyses excluding grade as a covariate considering the relatively high percentage of missing values for this variable, but this did not change the result of our analyses in any way. Neither did the additional analyses we performed adjusting for the execution of completion ALND. Separate unadjusted analyses of prognosis by N-stage according to whether patients received no adjuvant systemic therapy, adjuvant chemo-or hormonal therapy, or both did also not change the result of our analyses (Figs. 2,  3 , 4, and 5). 
Discussion
Based on the studies conducted before the introduction of the sentinel node procedure, administration of adjuvant systemic therapy to patients with micrometastatic disease in the sentinel node seems justifiable under the assumption that these micrometastases are prognostic indicators of worse survival and outcome. Our study, however, which is based exclusively on patients who underwent SNB, showed no overall survival difference between patients with micrometastatic disease and those without axillary lymph node metastasis. Even after adjustment for age, pT, grade, and administration of adjuvant systemic therapy, no significant survival differences could be detected. By using data of the Eindhoven Cancer Registry, we were able to present results based on a large, unselected population-based patient population. The patients were treated in both teaching and community hospitals, and data are thought to reflect the usual care in The Netherlands. This report is one of the first on the prognosis of patients with micrometastases in the sentinel node. Despite a fairly short follow-up time and a small number of events, the 95% confidence intervals of the estimated Hazard Ratios are small enough to rule out a large difference in survival between node-negative patients and patients with micrometastases.
Apparently, the biological behavior of sentinel node micrometastases is of limited prognostic significance, at least during the first 5 years after diagnosis. In order for tumor cells to metastasize, a number of sequential processes have to take place, such as tumor cell invasion, adhesion, and angiogenesis. This is a rather inefficient process, and not all circulating tumor cells are viable and capable of forming regional and distant metastasis [22] . Furthermore, expansion of metastasized tumor masses beyond 1-2 mm in diameter depends on the development of a new blood supply by angiogenesis, which again raises the question whether these very small metastases have biologic implications at all [23] . The observation that occult axillary and distant involvement might never become clinically overt [6, 24] led to the emergence of the stem cell hypothesis, which postulates that a population of cancer cells consists of a limited number of cancer stem cells that cause cancer progression and a larger number of non-stem cancer cells being dormant [25] . Presence of cancer stem cells in a metastatic focus is hypothesized to be important or possibly crucial for development and growth of these foci. Without these stem cells the metastatic focus would be destined to disappear by apoptosis or have a very long dormancy.
As stated before, studies on the significance of micrometastases, which used data from patients before the introduction of the SNB, showed contradicting results. In one of the larger studies with long follow-up, which was also based on data from the Eindhoven Cancer Registry, 10111 patients were included, of whom 179 had micrometastases. They were diagnosed with invasive breast cancer between 1975 and 1997 and had complete follow-up until April 2002. Remarkably, the results of this study showed that patients with axillary nodal micrometastasis in ALND had a significantly worse survival rate than node-negative patients independent of age or tumor size [14] . Since these Meier life table  analysis of survival by lymph  node status of patients who  underwent SNB for primary  breast cancer and received both  hormonal therapy and  chemotherapy, [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] data were derived from the same database, covering the same hospitals and pathology laboratories, we must conclude that ALND nodal micrometastases do not have the same prognostic implication as sentinel node micrometastases. We might have studied two different breast cancer patient populations with different tumor characteristics and metastatic tumor burden. This seems quite unlikely, however, since we adjusted for tumor stage and completion ALND, and other studies showed no change in prognosis during this period. Treatment plans have altered and have included the use of systemic adjuvant therapy far more often, but we adjusted for the possible effect of adjuvant systemic therapy in our study. Detection of metastases might be directly dependent on the methods used to investigate them. By using serial sectioning and immunohistochemistry in routine daily practice, more and smaller metastases are being detected, which may not be a harbinger of undetected macrometastases as may have been the case in older studies.
In an American publication, the SEER database was used to determine prognostic significance of micrometastases in pre-as well as post-SN era [26] . This relatively large study demonstrated only a minimal detrimental impact in tumors less than 2.0 cm in diameter and a more significant detrimental impact in larger tumors (1 vs. 4-6% decrease in 5-year survival). The authors, however, were not able to track the use of adjuvant therapies, and therefore, they could not adjust for the possible confounding effects of administration of adjuvant systemic therapy. Another Dutch publication based on a much smaller population sample showed that despite a higher risk of distant metastases in the micrometastatic group, there was no significant difference in overall or disease-free survival between pN0-and pN1mi-disease [27] . In a recently published study by Hansen et al. [28] , patients with isolated tumor cells or micrometastases did not have a worse disease-free and overall survival compared to SN-negative patients. Also consistent with our results was their finding that patients with macrometastases have a worse prognosis than the SN-negative patients and patients with isolated tumor cells or micrometastases.
The MIRROR study (Micrometasases and Isolated tumor cells: Relevant and Robust or Rubbish?) showed that patients with isolated tumor cells or micrometastases as final N-stage after SNB had a significantly lower 5-year disease-free survival than patients without nodal involvement [29] . This study, which is also a retrospective cohort study, only included patients with favorable tumor characteristics for whom adjuvant systemic treatment was not indicated according to the Dutch treatment guidelines. In contrast, we also included patients who had been receiving systemic treatment according to those guidelines, as well as patients with macrometastases to see how their prognosis compares to the prognosis of patients with micrometastastic disease or isolated tumor cells. In the MIRROR study, pathology of removed axillary lymph nodes was reviewed. Reviewing of the pathology seems to have led to a detection of more isolated tumor cells as compared to micrometastases and node-negative patients. We chose to base our analyses on the information that was retrieved from the pathology report and thus to present results based on usual care in The Netherlands. Finally, no data on overall survival were available in the MIRROR trial.
In conclusion, our population-based study showed that the presence of sentinel node micrometastases in breast cancer patients did not have significant impact on breast cancer overall survival during the first 5 years after diagnosis. We, therefore, postulate that micrometastatic disease itself should not be an indication for adjuvant systemic therapy.
